AU2001281099A1 - Production of human monoclonal antibodies - Google Patents

Production of human monoclonal antibodies

Info

Publication number
AU2001281099A1
AU2001281099A1 AU2001281099A AU8109901A AU2001281099A1 AU 2001281099 A1 AU2001281099 A1 AU 2001281099A1 AU 2001281099 A AU2001281099 A AU 2001281099A AU 8109901 A AU8109901 A AU 8109901A AU 2001281099 A1 AU2001281099 A1 AU 2001281099A1
Authority
AU
Australia
Prior art keywords
production
monoclonal antibodies
human monoclonal
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281099A
Inventor
Scott K. Dessain
Richard A. Goldsby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of AU2001281099A1 publication Critical patent/AU2001281099A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • C12N5/166Animal cells resulting from interspecies fusion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • C12N5/163Animal cells one of the fusion partners being a B or a T lymphocyte
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/04Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001281099A 2000-08-02 2001-08-01 Production of human monoclonal antibodies Abandoned AU2001281099A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22247300P 2000-08-02 2000-08-02
US60/222,473 2000-08-02
US09/759,984 2001-01-12
US09/759,984 US20020045219A1 (en) 2000-08-02 2001-01-12 Production of human monoclonal antibodies
PCT/US2001/024591 WO2002010352A2 (en) 2000-08-02 2001-08-01 Production of human monoclonal antibodies

Publications (1)

Publication Number Publication Date
AU2001281099A1 true AU2001281099A1 (en) 2002-02-13

Family

ID=26916832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281099A Abandoned AU2001281099A1 (en) 2000-08-02 2001-08-01 Production of human monoclonal antibodies

Country Status (3)

Country Link
US (1) US20020045219A1 (en)
AU (1) AU2001281099A1 (en)
WO (1) WO2002010352A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090570A2 (en) * 2001-05-08 2002-11-14 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
AU2002357932A1 (en) * 2001-12-18 2003-06-30 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
WO2006039400A2 (en) * 2004-09-29 2006-04-13 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639613A (en) * 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5645986A (en) * 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5686306A (en) * 1992-05-13 1997-11-11 Board Of Regents, The University Of Texas System Methods and reagents for lengthening telomeres
US5989807A (en) * 1992-05-13 1999-11-23 Geron Corporation & Board Of Regents Detecting cancerous conditions by assaying for telomerase activity
US5648215A (en) * 1992-05-13 1997-07-15 Board Of Regents, The University Of Texas System Telomerase diagnostic methods
US5837453A (en) * 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5693474A (en) * 1992-05-13 1997-12-02 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5629154A (en) * 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
WO1995013383A1 (en) * 1993-11-12 1995-05-18 Geron Corporation Methods and reagents for lengthening telomeres
US5804380A (en) * 1993-11-12 1998-09-08 Geron Corporation Telomerase activity assays
US5863726A (en) * 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
IL137101A0 (en) * 1998-01-12 2001-06-14 Cold Spring Harbor Lab Extension of cellular lifespan, methods and reagents

Also Published As

Publication number Publication date
WO2002010352A3 (en) 2003-02-27
US20020045219A1 (en) 2002-04-18
WO2002010352A2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
IL212419A0 (en) Methods of administering anti-tnf antibodies
AU1462300A (en) Human pan-hcv human monoclonal antibodies
AU2001294175A1 (en) Method of purifying antibody
AU2001259215A1 (en) Human anti-cd40 antibodies and methods of making and using same
AU2002256895A1 (en) Anti-TRAIL-R antibodies
HUP0402164A3 (en) Polycistronic expression of antibodies
EP1372718A4 (en) Production and use of novel peptide-based agents for use with bi-specific antibodies
PL354112A1 (en) Application of anti-ctla-4 antibodies
HK1061403A1 (en) ANTIBODIES TO HUMAN IL-1ß
AU2001280201A1 (en) Methods of synthesizing cell-free protein
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2002220843A1 (en) Humanised antibodies and uses thereof
AU2002365649A1 (en) Anti-dota antibody
AU5441000A (en) Human monoclonal antibody
AU2002251821A1 (en) Nicotine immunogens and antibodies and uses thereof
AU2001265935A1 (en) Production of biohydrolysates
AU2003260871A1 (en) Hybridomas producing high levels of human sequence antibody
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
AU2001280368A1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy
AU2001281099A1 (en) Production of human monoclonal antibodies
AU1735801A (en) Antibody against human kgfr
AU2002221132A1 (en) Novel antibody
AU2002242447A1 (en) Use of polyclonal immunoglobulins
AUPQ743300A0 (en) Separation of avian antibodies
AU2002210855A1 (en) Synthesis of fused pyrrolecarboxamides